Sei Investments Co. boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.4% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 43,446 shares of the company’s stock after acquiring an additional 4,102 shares during the period. Sei Investments Co.’s holdings in IDEXX Laboratories were worth $6,756,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. WMS Partners LLC grew its holdings in IDEXX Laboratories by 0.3% in the 2nd quarter. WMS Partners LLC now owns 1,583 shares of the company’s stock valued at $256,000 after buying an additional 4 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its holdings in IDEXX Laboratories by 0.3% in the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,547 shares of the company’s stock valued at $1,057,000 after buying an additional 19 shares in the last quarter. CAPROCK Group Inc. grew its holdings in IDEXX Laboratories by 2.2% in the 2nd quarter. CAPROCK Group Inc. now owns 1,830 shares of the company’s stock valued at $295,000 after buying an additional 40 shares in the last quarter. Strs Ohio grew its holdings in IDEXX Laboratories by 0.7% in the 2nd quarter. Strs Ohio now owns 5,929 shares of the company’s stock valued at $957,000 after buying an additional 41 shares in the last quarter. Finally, National Asset Management Inc. grew its holdings in IDEXX Laboratories by 2.1% in the 2nd quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock valued at $332,000 after buying an additional 42 shares in the last quarter. Institutional investors and hedge funds own 88.41% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “IDEXX Laboratories, Inc. (IDXX) Shares Bought by Sei Investments Co.” was originally published by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/idexx-laboratories-inc-idxx-shares-bought-by-sei-investments-co/1723153.html.

A number of brokerages have commented on IDXX. CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 price objective on the stock in a report on Friday, July 28th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $185.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Bank of America Corporation raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 price objective on the stock in a report on Wednesday, August 23rd. Canaccord Genuity reaffirmed a “buy” rating and issued a $180.00 price objective on shares of IDEXX Laboratories in a report on Tuesday, August 22nd. Finally, Zacks Investment Research lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. IDEXX Laboratories presently has a consensus rating of “Hold” and a consensus target price of $173.67.

In other news, Chairman Jonathan W. Ayers sold 54,000 shares of the stock in a transaction on Tuesday, November 7th. The stock was sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the sale, the chairman now directly owns 1,064,573 shares of the company’s stock, valued at approximately $161,091,186.36. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Jonathan W. Ayers sold 18,000 shares of the stock in a transaction on Thursday, November 16th. The stock was sold at an average price of $153.61, for a total value of $2,764,980.00. Following the sale, the chief executive officer now directly owns 1,064,573 shares in the company, valued at $163,529,058.53. The disclosure for this sale can be found here. Over the last three months, insiders have sold 121,000 shares of company stock worth $18,334,330. 2.77% of the stock is currently owned by insiders.

IDEXX Laboratories, Inc. (IDXX) opened at $154.06 on Friday. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. IDEXX Laboratories, Inc. has a 1-year low of $113.47 and a 1-year high of $173.01. The company has a market capitalization of $13,436.91, a price-to-earnings ratio of 51.87, a price-to-earnings-growth ratio of 2.33 and a beta of 0.46.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.05. The firm had revenue of $492.00 million for the quarter, compared to analyst estimates of $492.94 million. IDEXX Laboratories had a negative return on equity of 336.64% and a net margin of 14.55%. The company’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.62 EPS. equities research analysts predict that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.